E-mail

E-mail a Wiley Online Library Link

George R. Simon, Martine Extermann, Alberto Chiappori, Charles C. Williams, Mubeena Begum, Rachna Kapoor, Eric B. Haura, Roohi Ismail-Khan, Michael J. Schell, Scott J. Antonia and Gerold Bepler Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older Cancer 112

Version of Record online: 25 FEB 2008 | DOI: 10.1002/cncr.23360

Docetaxel combined with gefitinib is active and well tolerated in chemonaive patients with advanced nonsmall-cell lung cancer who are aged ≥70 years. Median survivals were 22.8 months in women and 4.8 months in men, indicating that female sex-specific confirmatory clinical trials with this regimen are warranted.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

SEARCH